close-up of edward morgan in lab coat
Dr. Edward L. Morgan
 


Edward L. Morgan, Ph.D.

Research Professor


Program Area

Translational Cell Biology and Molecular Biology


Reserach Interests

Utilization of naturally occurring mediators (biological response modifiers) to improve vaccine development, design of new therapeutics for the treatment of antibiotic resistant bacteria (MRSA) as well as viral ( Hepatitis C and HIV) and fungal (Valley Fever) diseases in both young and aged individuals. Military applications for the treatment of infections in the battlefield as well as bio-terrorism.


Education/Training

University of Arizona, Tucson, AZ / B.S. 1974 / Medical Microbiology
University of California, Berkeley, CA / Ph.D. 1978 / Immunology and Microbiology,
Scripps Clinic and Research Foundation, La Jolla, CA / Postdoc Fellow 1978-1981 / Immunopathology




Positions and Employment

1981-1986 Assistant Member, Department of Immunopathology/Immunology, Scripps Clinic and Research Foundation, La Jolla, CA.

1986-1997 Associate Member, Department of Immunology, The Scripps Research Institute, La Jolla, CA.

1997-2005 Director, Biological Assay Development Group/Biological Response Modifier Group, BD Biosciences, San Diego, CA.

2005-2006 Vice President, Product Development and Licensing, Gen Way Biotech, San Diego, CA.

2006-2008 Adjunct Associate Professor, Sidney Kimmel Cancer Center, San Diego, CA.

2008-2009 Professor in Residence, Sidney Kimmel Cancer Center, San Diego, CA.

2009-present Research Professor of Immunology, San Diego State University Biosciencescience Center, San Diego, CA.

2009-present Adjunct Professor, Department of Biology, San Diego State University, San Diego, CA.


Memberships, Honors, and Awards

1978-1979 Damon Runyon-Walter Winchell Cancer Fund Fellowship.

1979-1981 United States Public Health Service, National Cancer Institute, Postdoctoral Fellowship.

1980-present The American Association of Immunologists.

1981-1986 United States Public Health Service, National Cancer Institute, Research Career Development Award.

1987-1991 Member, Merit Review Board for Immunology, Veterans Administration.

1994-present Associate Editor, International Journal of Immunopharmacology.

1995-1999 Member, National Dental Institute, Oral Biology and Medicine Study Section.

2005-present The American Association of Cell Biology.


Patents

1983 E. L. Morgan and W.O. Weigle: Design of Immunoadjuvants from Human Immunoglobulin.

1995 E. L. Morgan, W.O. Weigle, and T.E. Hugli: Design of Neo-epitope Specific Antibodies to Human Complement C5a Receptors.




Selected Peer-Reviewed Publications

  1. Phillips, J., Morgan, E.L., Dong, Y., Cole, G., McMahan, C., Hung, C-Y., and S. Sanderson. Single-Step Conjugation of Bioactive Peptides to Proteins via a Self-Contained Succinimidyl Bis-Arylhydrazone. Bioconjugate Chemistry (in press).

  2. Morgan, E. L., Morgan, B. N., Stein, E. A., Vitrs, E. A, Thoman, M. L., Sanderson, S. D., and J. A. Phillips. EP67: a C5a Receptor Agonist Peptide That Acts as a Potent Adjuvant. Vaccine (in press).

  3. Morgan E. L., R. Varro, H. Sepulveda, J.A. Ember, J. Apgar, J. Wilson, L. Lowe et al. Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clin Immunol 110:252, 2004.

  4. Hodge G, S. Hodge, R. Haslam, A. McPhee, H. Sepulveda, E. L. Morgan, I. Nicholson, H. Zola. Rapid simultaneous measurement of multiple cytokines using 100 ml sample volumes-association with neonatal sepsis. Clin Exp. Immunol. 137:402, 2004.

  5. Morgan E. L., Varro R, Sepulveda H, Ember J.A., Apgar J, Wilson J, Lowe L., et al (2004). Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clin Immunol 110:252.

  6. Hodge G, Hodge S., Haslam R., McPhee A., Sepulveda H., Morgan E.L., Nicholson I., Zola H. (2004). Rapid simultaneous measurement of multiple cytokines using 100 μl sample volumes-association with neonatal sepsis. Clin Exp Immunol. 137:402.

  7. Cooke E.B., J. L. Stahl, L. Lowe L, Morgan, E.L. et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J. Immunol Meth 254:109, 2001.

  8. Floreani A.A., Heires A.J., Welniak L.A., Miller-Lindholm A., Clark-Pierce L., Rennard S.I., Morgan E.L., and Sanderson, S.D. (1998). Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J. Immunol. 15:5073.

  9. Buchner, R., Vogen, S.W., Sanderson S.D., Fisher W., Thoman M.L., and Morgan. E.L. (1997). Characterization of site-directed neutralizing antibodies specific for the amino-terminal region of the human Kappa receptor. J. Immunol. 58:1670.

  10. Tempero, R.M., Hollingworth, M.A., Burdick M.D., Finch A.M., Taylor S.M., Vogen S.M., Morgan E.L., and Sanderson, S.D. (1997). Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J. Immunol. 158:1377.

  11. Morgan, E.L. (1996). Suppression of antibody synthesis by human B lymphocytes by μ, δ, and κ opioid receptor selective agonists. J. Neuro. Immunol. 65:21.

  12. Buchner, R., Hugli T.E., and Morgan E.L. (1995). Expression of functional receptors for human C5a anaphylatoxin on the human hepatocellular carcinoma cell line HepG2. J. Immunol. 155:308.

  13. Ember, J.A., Sanderson S.D., Hugli, T.E. and Morgan E.L (1994). Induction of IL-8 synthesis from monocytes by human C5a. Am. J. Pathol. 144:393.

  14. Morgan, E.L., Ember J.A., Sanderson S.D., Scholz W., Buchner R., Ye, R.D., and Hugli T.E. (1993). Anti-C5a receptor antibodies. I. Characterization of neutralizing antibodies specific for the human C5a receptor. J. Immunol. 151:377.

  15. Morgan, E.L. (1993). Complement fragment C5a and Imunoregulation. Complement Profiles 1:56.

  16. Morgan, E.L., Sanderson S., Scholz, W., Noonan D.J., Weigle W.O., and Hugli T.E. (1992). Identification & characterization of the effector region within human C5a responsible for stimulation of interleukin 6 synthesis. J. Immunol. 148:3937.

  17. Morgan, E.L., McClurg, M.R. and Janda,J.A. (1990) β-endorphin-mediated suppression of human lymphocyte activation. J. Neuroimmunol. 28:209.

  18. Scholz, W., McClurg M.R., Noonan, D.J., Cardenas G.J., Smith M., Hugli T.E., and Morgan, E.L. (1990). C5a-mediated release of interleukin-6 by human monocytes. Clin. Immunol. Immunopath. 57:297.

  19. Morgan, E.L. and Weigle, W.O. (1987). Biological activities residing in the Fc region of immunoglobulin. Adv. Immunol. 40:61.

  20. Morgan, E.L. (1987). Role of prostaglandins in C3a-mediated suppression of human in vitro polyclonal antibody responses. Clin. Immunol. Immunopathol. 44:1.

  21. Morgan, E.L. (1986). Modulation of the immune response by anaphylatoxins. Complement 3:128.

  22. Hobbs, M.V., Morgan, E.L., Baker N.L., and Weigle, W.O. (1985). Regulation of antibody responses by rheumatoid factor. I. Polyclonal activation of human B cells by rheumatoid factor-containing preparations from seropositive plasma. J. Immunol. 134:223.

  23. Hobbs, M.V., Morgan E.L., Scheuer, W.V. and Weigle, W.O. (1985). Binding and processing of immunostimulatory Fc fragments by the murine macrophage cell line P388D1. Cell. Immunol. 90:74.

  24. Hugli, T.E. and Morgan, E.L. (1984). Mechanisms of leukocyte regulation by complement-derived factor. Cont. Topics Immunobiol. 14:109.

  25. Thoman, M.L., Meuth J.L., Morgan E.L., Weigle, W.O. and Hugli, T.E. (1984) C3d- K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J. Immunol. 133:2629.

  26. Morgan, E.L., Thoman M.L., Weigle, W.O. and Hugli, T.E. (1983). Anaphylatoxin- mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune response. J. Immunol. 130:1257.

  27. Morgan, E.L., Weigle, W.O., Erickson B.W., Fok K, and Hugli, T.E. (1983). Suppression of humoral immune responses by synthetic C3a peptides. J. Immunol. 131:2258.

  28. Meuth, J.L., Morgan E.L., DiScipio, R.G. and Hugli T.E. (1983). Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b. J. Immunol. 130:2605.

  29. Morgan, E.L., Shields, J.E., Campbell, C.S., Barton R.L., Koppel, G.A. and Weigle, W.O. (1983). Synthetic Fc peptide-mediated regulation of the immune response. I. Characterization of the immunomodulatory properties of a synthetic 23-amino acid peptide derived from the sequence of the CH3 domain of human IgG1. J. Exp. Med. 157:947.

  30. Morgan, E.L., Weigle, W.O. and Hugli, T.E. (1982). Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune response. J. Exp. Med. 155:1412.

  31. Morgan, E.L. and Weigle, W.O. (1982). The immune response in aged C57Bl/6 mice. II. Characterization and reversal of a defect in the ability of aged spleen cells to respond to the adjuvant properties of Fc fragments. J. Immunol. 129:36.

  32. Morgan, E.L., Hugli, T.E. and Weigle, W.O. (1982). Isolation and identification of a biologically active peptide derived from the CH3 domain of human IgG1. Proc. Natl. Acad. Sci. USA 79:5388.

  33. Morgan, E.L., Thoman, M.L. and Weigle, W.O. (1981). The immune response in aged C57BL/6 mice. I. Assessment of lesions in the B-cell and T-cell compartments of aged mice utilizing the Fc fragment-mediated polyclonal antibody response. Cell. Immunol. 63:16.

  34. Morgan, E.L. and Weigle, W.O. (1981). Polyclonal activation of human B lymphocytes by Fc fragments. I. Characterization of the cellular requirements for Fc fragment-mediated polyclonal antibody secretion by human peripheral blood B lymphocytes. J. Exp. Med. 154:778.

  35. Walker, S.M., Morgan, E.L. and Weigle, W.O. (1981). Regulation of the in vitro secondary antibody response. II. Antigen-induced murine splenic T cell proliferation. J. Immunol. 126:766.

  36. Fidler, J.M., Morgan, E.L. and Weigle, W.O. (1980). B lymphocyte differentiation in the CBA/N mouse: A delay in maturation rather than a total arrest. J. Immunol. 124:13.

  37. Morgan, E.L., Fidler, J. M. and Weigle, W.O. (1980). The inability of CBA/N mice to proliferate in response to Fc fragments from human immunoglobulin is an age-related defect. Cell. Immunol. 50:445.

  38. Morgan, E.L. and Weigle, W.O. (1980). Regulation of Fc fragment-induced murine spleen cell proliferation. J. Exp. Med. 151:1.

  39. Thoman, M.L., Morgan, E.L. and Weigle, W.O. (1980). Polyclonal activation of murine B lymphocytes by Fc fragments. II. Replacement of T cells by a soluble helper T cell-replacing factor (TRF). J. Immunol. 125:1630.

  40. Morgan, E.L. and W.O. Weigle, W.O. (1979) Macrophage requirement in the Fc fragment- induced proliferative response of murine spleen cells. J. Exp. Med. 150:256.

  41. Morgan, E.L., Spiegelberg, H.L. and Weigle, W.O. (1979). Comparison of the binding of radiolabeled human IgG and Fc fragments to mouse spleen cells. Scand. J. Immunol. 10:395.

  42. Morgan, E.L. and Tempelis, C.H. (1977) The role of antigen-antibody complexes in immunological unresponsiveness in the chicken. J. Immunol. 119:1293.